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Gene transfer experiments have made it possible to detect
active transforming sequences in the DNA of various human
tumor cells. These sequences, the cellular oncogenes, have
been found in tumors as diverse as neuroblastomas, leuke-
mias, carcinomas, and sarcomas . They appear to represent
molecular determinants that participate in transformation
mechanisms that are common to a wide variety of tumors .
From this perspective, cancer seems to be a single, unitary
disease, and not 100 different diseases, each characterized by
a different type of tumor.
Several ofthese oncogenes have been isolated by molecular
cloning (1-4) . The most well studied of these is one from a
human bladder carcinoma cell line, referred to as T24/EJ .
Use of this oncogene in sequence hybridization has revealed
a property common to this and the other cellular oncogenes :
these oncogenes derive from closely related antecedent genes
residing in the normal cellular genome . It appears that these
normal genes, often called "proto-oncogenes," become con-
verted into oncogenes via processes of "somatic mutation."
This last conclusion remains equivocal, if only because there
is little direct evidence to date showing comparison of the
oncogene of a tumor with the homologous sequences of
closely lying normal tissue .
A variety of mechanisms might be imagined to be respon-
sible for the conversion of a proto-oncogene into an active
oncogene. In the case of the bladder carcinoma oncogene, a
remarkably simple mechanism was revealed within the last
year . Comparison ofthe bladder carcinoma oncogene with its
normal antecedent showed that a single nucleotide alteration,
occurring in the protein-encoding portion of the gene, was
responsible for the activation . This point mutation affected
the twelfth amino acid of the encoded 21,000-dalton protein
causing the replacement of a glycine by a valine (5-9). Since
little is known about the functioning of this protein, it is
impossible at present to explain how such a subtle alteration
can have such profound effects on this protein, and in turn,
on cellular physiology .
This bladder carcinoma proto-oncogene has homologs in
the DNA of all vertebrates . Its evolutionary origins can,
however, be traced back much further. Sequence hybridiza-
tion has found homologs of this and other proto-oncogenes
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in the DNA of Drosophila melanogaster (10) . This leads to
the realization that these genes are of extremely ancient
lineage-their precursors were already present in similar form
in the primitive metazoans that served as common ancestors
to chordates and arthropods . Such conservation indicates that
these genes have served vital, indispensable functions in nor-
mal cellular and organismic physiology, and that their role in
carcinogenesis represents only an unusual and aberrant diver-
sion from their usual functions.
Because these oncogenes are of truly cellular origin, it is
perhaps paradoxical to learn that they were originally discov-
ered, not via gene transfer ofcellular DNA, but through their
association with transforming retroviruses. Thus, we now
know that the bladder carcinoma oncogene is the same on-
cogene that had previously been described as part of the
genome of Harvey rat sarcoma virus. An oncogene found by
gene transfer in lung and colon tumors was the same oncogene
as that found in Kirsten rat sarcoma virus (11, 12) . In the
case of both of these viruses, it is known that their oncogenes
were derived by acquisition of a proto-oncogene from the
genome of the rat. Therefore, a proto-oncogene can become
activated in two independent ways : by somatic mutation (in
humans) or by a retrovirus (in rodents).
The oncogenes described above are members of the ras
gene family, originally named because of associations with
these rat sarcoma viruses. The gene family has three members
that are known to be active in tumors of nonviral etiology :
Ha-ras, Ki-ras, and N-ras. Among the human tumors that
carry oncogenes, the Ha-ras has been found in the above-
mentioned bladder carcinoma and in skin carcinomas ; the
Ki-ras in various colon, lung, and pancreatic carcinomas, and
several sarcomas ; and the N-ras in a variety of hematopoietic
malignancies, a neuroblastoma, sarcomas, and a colon carci-
noma (13, 14) .
These data reveal two aspects about the relationship ofeach
oncogene with these various tumors. First, each proto-onco-
gene can become activated in a variety of tissue types . And
second, once activated, the resulting oncogene apparently is
able to help transform the cells ofthese various tissues. There
is yet a third related conclusion that comes from these data:
a given type of tumor cannot, with any certainty, be traced
back to a known oncogene . For example, a colon carcinoma
will most likely carry a Ki-ras oncogene, but may on occasion
be found to carry an active N-ras allele within its cells .
Although these ras genes appear diverged from one another
1661by hundreds of millions of years of evolution, their encoded
gene products are remarkably similar, having as much as90%
identity in amino acid sequence (15, 16) . This speaks to the
importance of their structure in normal cellular physiology.
Any substantial deviations from an earlier ancestral sequence
has obviously not been tolerated during evolution .
Current research efforts are designed to relate these molec-
ular observations with the biological complexities of the car-
cinogenic process . One area ofinterest focuses on the apparent
contrast between the results of gene transfer (transfection)
and the known multi-step nature of carcinogenesis in vivo .
The oncogene transfection has involved use of NIH3T3
mouse fibroblasts, which are converted into tumor cells in a
one-step process, and it is difficult to reconcile this observation
with the multiple hits thought to be required in the course of
natural tumorigenesis.
One resolution of this paradox has come from the realiza-
tion that the NIH3T3 cells, being established and immortal-
ized in vitro, are themselves highly abnormal . Perhaps they
have undergone many predisposing alterations during their
adaptation to continuous culture, and are now primed for the
final hit-the acquisition of a ras oncogene . This idea is
vindicated by recent work in our laboratory, which shows that
embryo fibroblasts, unlike the extensively passaged NIH3T3
cells, are not transformed into tumor cells by an introduced
ras oncogene (17),
Such work indicates that a ras oncogene requires other
cooperating alterations to the cell for the full phenotype of
transformation to be realized . One such cooperating alteration
is supplied by the establishment/immortalization process. An
alternative is provided by other oncogenes . For example, if a
ras oncogene is introduced together with a second oncogene,
such as a myc cellular oncogene or polyoma virus large T
gene, then transformation of the embryo cells is achieved .
This begins to provide a molecular model of multi-step car-
cinogenesis, following which several of the critical steps in-
volve activation ofdistinct cellular oncogenes (e.g., ras, myc) .
Moreover, it shows that oncogenes are not all functionally
identical . Instead, it seems that different oncogenes have
distinct and occasionally complementary roles to play in the
transformation process.
These results only begin to explain the cancer process . Some
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basic questions remain unresolved . Why do only 20% of
human tumors tested yield oncogenes upon transfection?
Howmany oncogenes need cooperate to create most naturally
occurring tumors?And perhaps most intractable, how do the
oncogene proteins function to exert such global effects on
cellular physiology? We have not even begun to find the
answers to these challenging questions .
Receivedand acceptedfor publication 23 August 1983.
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